Clinical trial
Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or…
NCT00003992 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00003992 |
|---|---|
| Title | Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2 |
| Official title | Pilot Trial of Paclitaxel-Herceptin Adjuvant Therapy for Early Stage Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate |
| Enrollment | 200 |
| Start date | Aug 1, 1999 |
| Primary completion | Jan 1, 2007 |
| Completion | Mar 1, 2009 |
| First posted | Jun 9, 2004 |
| Last update posted | Jun 3, 2013 |
| Countries | South Africa, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: